Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 21, 1987 - Issue 1
Submit an article Journal homepage
4
Views
14
CrossRef citations to date
0
Altmetric
Original papers

Weekly Low-Dose Adriamycin in Hormone-Resistant Metastatic Cancer of the Prostate

Sophie D. FossåDepartments of Medical Oncology and Radiotherapy, Biophysics, Norsk Hydros Institute for Cancer Research, the Norwegian Radium Hospital, Oslo
,
Thomas UrnesSurgical Department, Vestfold Central Hospital, Tønsberg, Norway
&
Olav KaalhusSurgical Department, Vestfold Central Hospital, Tønsberg, Norway
Pages 13-16 | Received 03 Dec 1985, Published online: 15 Feb 2010

REFERENCES

  • Beynon LL, Chisholm GD. The stable state is not an objective response in hormone-escaped carcinoma of prostate. Br J Urol 1984; 56: 702–705.
  • Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR. Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluo-rouracil (VSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial. Cancer 1978; 42: 2546–2552.
  • Chlebowski RT, Paroly WS, Pugh RP et al. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1978; 64: 47–51.
  • Eagan RT, Hahn RG, Myers RP. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 1976; 60: 115–117.
  • Fosså SD, Jahnsen JU, Karlsen S, Øgreid P, Haveland H, Trovåg A. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study. Eur Urol 1985; 11: 11–16.
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
  • Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39.
  • Robinson MRG, Chandrysekran S, Newling DWW, Richards B, Smith PH. Low-dose doxorubicin in the management of advanced carcinoma of the prostate. Br J Urol 1983; 55: 747–748.
  • Scher H, Yagoda A, Watson RC, Serber M, Whitmore W. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984; 131: 1099–1102.
  • Torti FM, Aston D, Lum BL, Kohler M et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983; 1: 477–482.
  • DeWys WD, Begg CB, Brodovsky H, Creech R, Khandekar J. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response. The Prostate 1983; 4: 1–11.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.